Pasireotide LAR
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acromegaly
Conditions
Acromegaly, Pituitary Gigantism
Trial Timeline
Oct 16, 2012 → Apr 10, 2017
NCT ID
NCT01673646About Pasireotide LAR
Pasireotide LAR is a phase 2 stage product being developed by Novartis for Acromegaly. The current trial status is completed. This product is registered under clinical trial identifier NCT01673646. Target conditions include Acromegaly, Pituitary Gigantism.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02354508 | Phase 3 | Completed |
| NCT01283542 | Phase 2 | Completed |
| NCT01673646 | Phase 2 | Completed |
| NCT01364415 | Phase 1 | Completed |
| NCT00958841 | Phase 2 | Terminated |
Competing Products
20 competing products in Acromegaly
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alesse | Novartis | Phase 2 | 52 |
| ONO-5788 + ONO-5788 Placebo + Octreotide | Ono Pharmaceutical | Phase 1 | 33 |
| ONO-5788 + [14C]-ONO-5788 | Ono Pharmaceutical | Phase 1 | 33 |
| Pasireotide LAR | Novartis | Phase 3 | 77 |
| Octreotide acetate 30 mg suspension | Novartis | Phase 3 | 77 |
| Pasireotide long acting release formulation | Novartis | Pre-clinical | 23 |
| Sandostatin LAR + pegvisomant + cabergoline | Novartis | Approved | 85 |
| Octreotide acetate and cabergoline/Octrotide and Somavert | Novartis | Approved | 85 |
| Sandostatin LAR | Novartis | Approved | 85 |
| Pasireotide + Octreotide | Novartis | Phase 3 | 77 |
| Sandostatin (Octreotide Acetate) | Novartis | Approved | 85 |
| Octreotide acetate | Novartis | Approved | 85 |
| octreotide FluidCrystal® injection depot | Novartis | Phase 2 | 52 |
| Octreotide LAR | Novartis | Phase 3 | 77 |
| Octreotide LAR | Novartis | Phase 3 | 77 |
| Pasireotide | Novartis | Phase 2 | 52 |
| Pasireotide LAR 60 mg + Pegvisomant | Novartis | Approved | 85 |
| Octreotide | Novartis | Approved | 85 |
| Octreotide LAR 30 MG Injection | Novartis | Approved | 85 |
| Pasireotide (SOM230), Octreotide (Sandostatin) | Novartis | Phase 2 | 52 |